High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma.
暂无分享,去创建一个
W. Klapper | F. Jardin | E. Hoster | G. Salles | F. Berger | O. Casasnovas | P. Feugier | E. Macintyre | C. Pott | C. Haioun | M. Dreyling | O. Hermine | V. Ribrag | M. Unterhalt | C. Thieblemont | J. Brière | M. Delfau-Larue
[1] S. Swerdlow. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .
[2] M. Ladetto,et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] K. Seitz. Mantelzell-Lymphom , 2016, Z Ultraschall in der Medizin.
[4] E. Hsi,et al. Combination of ibrutinib with ABT‐199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways , 2015, British journal of haematology.
[5] Michael E. Williams,et al. Synergistic Cytotoxicity of Ibrutinib and the BCL2 Antagonist, ABT-199(GDC-0199) in Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL): Molecular Analysis Reveals Mechanisms of Target Interactions , 2014 .
[6] J. Byrd,et al. A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). , 2014, Blood.
[7] W. Klapper,et al. Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] J. Delabie,et al. SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma – a Nordic Lymphoma Group study , 2014, British journal of haematology.
[9] M. Wang,et al. Combinatorial drug screening identifies synergistic co-targeting of Bruton's tyrosine kinase and the proteasome in mantle cell lymphoma , 2013, Leukemia.
[10] M. Cazzola,et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. , 2012, Blood.
[11] H. Kluin-Nelemans,et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] J. Drach,et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Michael L. Wang,et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. , 2013, The New England journal of medicine.
[14] G. Salles,et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. , 2013, Blood.
[15] E. Campo,et al. Molecular pathogenesis of mantle cell lymphoma. , 2012, The Journal of clinical investigation.
[16] J. Vose. Mantle cell lymphoma: 2012 update on diagnosis, risk‐stratification, and clinical management , 2012, American journal of hematology.
[17] A. Rosenwald,et al. The complex landscape of genetic alterations in mantle cell lymphoma. , 2011, Seminars in cancer biology.
[18] D. Halley,et al. Multiplex ligation-depending probe amplification is not suitable for detection of low-grade mosaicism , 2011, European Journal of Human Genetics.
[19] W. Klapper. Histopathology of mantle cell lymphoma. , 2011, Seminars in hematology.
[20] M. Dreyling,et al. Treatment of younger patients with mantle cell lymphoma. , 2011, Seminars in hematology.
[21] R. Siebert,et al. Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma , 2010, Genes, chromosomes & cancer.
[22] W. Klapper,et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. , 2010, Blood.
[23] F. Jardin,et al. Detection of gene copy number aberrations in mantle cell lymphoma by a single quantitative multiplex PCR assay: clinicopathological relevance and prognosis value , 2009, British journal of haematology.
[24] Jeroen van der Laak,et al. Ki-67 as a prognostic marker in mantle cell lymphoma—consensus guidelines of the pathology panel of the European MCL Network , 2009, Journal of hematopathology.
[25] J. Leonard,et al. Outcome of deferred initial therapy in mantle-cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] E. Hoster,et al. Improvement of overall survival in advanced stage mantle cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] J. Leonard,et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] E. González-Barca,et al. Multiplex ligation‐dependent probe amplification for detection of genomic alterations in chronic lymphocytic leukaemia , 2008, British journal of haematology.
[29] A. Rosenwald,et al. Delineation of distinct tumour profiles in mantle cell lymphoma by detailed cytogenetic, interphase genetic and morphological analysis , 2008, British journal of haematology.
[30] H. Müller-Hermelink,et al. Genomic aberrations in mantle cell lymphoma detected by interphase fluorescence in situ hybridization. Incidence and clinicopathological correlations , 2008, Haematologica.
[31] F. Jardin,et al. Detection of somatic quantitative genetic alterations by multiplex polymerase chain reaction for the prediction of outcome in diffuse large B-cell lymphomas , 2008, Haematologica.
[32] W. Klapper,et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. , 2008, Blood.
[33] Martin Dreyling,et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. , 2006, Blood.
[34] L. Staudt,et al. Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] W. Klapper,et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network , 2005, British journal of haematology.
[36] A. Rosenwald,et al. Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] D. Pinkel,et al. Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. , 2005, Blood.
[38] E. Hoster,et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the Germa , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] G. Ott,et al. Genomic DNA-chip hybridization in t(11;14)-positive mantle cell lymphomas shows a high frequency of aberrations and allows a refined characterization of consensus regions. , 2004, Blood.
[40] A. Hagemeijer,et al. Coexistence of BCL1/CCND1 and CMYC aberrations in blastoid mantle cell lymphoma: a rare finding associated with very poor outcome , 2004, Annals of Hematology.
[41] M Hummel,et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936 , 2003, Leukemia.
[42] L. Staudt,et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. , 2003, Cancer cell.
[43] W. Sanger,et al. Mantle Cell Lymphoma with 8q24 Chromosomal Abnormalities: a Report of 5 Cases with Blastoid Features , 2002, Modern Pathology.
[44] P. Guldberg,et al. Concurrent disruption of p16INK4a and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin's lymphoma , 2000, Leukemia.
[45] A. López-Guillermo,et al. INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene. , 2000, The American journal of pathology.
[46] W. Hiddemann,et al. Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma. , 1997, Cancer research.
[47] B. Nathwani,et al. A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project , 1997 .
[48] James Olen Armitage,et al. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. , 1997, Blood.
[49] E. Campo,et al. Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. , 1997, Blood.
[50] H Stein,et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.
[51] K. Lennert,et al. Growth fractions in malignant non‐Hodgkin's lymphomas (NHL) as determined in situ with the monoclonal antibody Ki‐67 , 1984, Hematological oncology.